Home › Research › Treatments
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial
Mintzer J, Greenspan A, Caers I, Van Hove I, Kushner S, Weiner M, Gharabawi G, Schneider LS.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006-03-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD). Method The authors conducted a randomized, eight-week, double-blind, placebo-controlled, multicenter trial involving nursing home residents diagnosed with AD and psychosis. Four hundred seventy-three patients were randomly assigned to placebo (N = 238) or 1.0 to 1.5 mg risperidone per day (N = 235). Coprimary efficacy end points were: changes in scores on the Behavioral pathology in Alzheimer's Disease (BEHAVE-AD) Psychosis subscale and Clinical Global Impression of Change (CGI-C). Protocol-specified subgroup analyses were performed by demographics and dementia severity. Results Efficacy analysis included 416 patients. Both groups improved significantly on the BEHAVE-AD Psychosis subscale and CGI-C with no significant difference between groups. In the subgroups analyses, a statistically significant treatment by Mini-Mental Status Examination (MMSE) interaction on the CGI-C (F([2,381]) = 3.90, p = 0.021) was observed with patients with more severe dementia (MMSE Conclusion This trial did not confirm earlier findings in this population.
What this study adds
Evidence grade: High
This is a trial of 238 participants. In 416 analyzed nursing home residents with Alzheimer's disease and psychosis, both risperidone and placebo groups improved on psychosis and global change measures with no significant difference between groups, and the trial did not confirm earlier findings. Reported effect size: or 1.0.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mintzer, J., Greenspan, A., Caers, I., Van Hove, I., Kushner, S., Weiner, M., et al. (2006). Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. https://doi.org/10.1097/01.jgp.0000194643.63245.8c
Vancouver
Mintzer J, Greenspan A, Caers I, Van Hove I, Kushner S, Weiner M, et al. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2006. doi:10.1097/01.jgp.0000194643.63245.8c. PMID: 16505133.
BibTeX
@article{mintzer2006-16505133,
author = {Mintzer, J. and Greenspan, A. and Caers, I. and Van Hove, I. and Kushner, S. and Weiner, M. and Gharabawi, G. and Schneider, L. S.},
title = {{Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial}},
journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
year = {2006},
doi = {10.1097/01.jgp.0000194643.63245.8c},
pmid = {16505133},
url = {https://doi.org/10.1097/01.jgp.0000194643.63245.8c}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results Efficacy analysis included 416 patients.
- Both groups improved significantly on the BEHAVE-AD Psychosis subscale and CGI-C with no significant difference between groups.
- In the subgroups analyses, a statistically significant treatment by Mini-Mental Status Examination (MMSE) interaction on the CGI-C (F([2,381]) = 3.90, p = 0.021) was observed with patients with more severe dementia (MMSE Conclusion This trial did not confirm earlier findings in this population.
Why it matters
In 416 analyzed nursing home residents with Alzheimer's disease and psychosis, both risperidone and placebo groups improved on psychosis and global change measures with no significant difference between groups, and the trial did not confirm earlier findings. It did not show that risperidone treats psychosis of Alzheimer's disease better than placebo.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants238
- Effect sizeor 1.0
- Evidence strengthHigh
How this study scored 64/100
Published in a peer-reviewed journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry) |
| Journal's citation record | 2 / 4 | American Journal of Geriatric Psychiatry: journal h-index 178 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 2 / 4 | 238 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 94 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.3 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 3 / 6 | Cited 4.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Lon S. S. Schneider: h-index 87 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Medical University of South Carolina: institution h-index 715 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16505133) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.